Credgenics

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Qi enhances its customer service with Genesys' Generative AI and Cloud technology, achieving an 80% reduction in response time and 60% telecom cost savings.

Medical errors are the third leading cause of death in the U.S., contributing to over 250,000 preventable deaths each year. NeuralCure AI is tackling this crisis head-on by eliminating diagnostic blind spots and accelerating treatment precision with its cutting-edge AI-driven decision support system.

Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.

This new approach, powered by a specialised protein large language model, predicts the most effective protein variants while using 99% less data than traditional methods.

AI-driven genomics startups leverage technology to analyze genetic data, predict predispositions, and offer personalized health recommendations.

Tevogen Bio has expanded its partnership with Microsoft, aiming to further its AI-centred collaboration and advance its predictive precision T-cell targeting technology, PredicTcell.